LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 9 of total 9

Search options

  1. Article ; Online: Are the cut-offs of the rheumatoid factor and anti-cyclic citrullinated peptide antibody different to distinguish rheumatoid arthritis from their primary differential diagnoses?

    Pineda-Sic, Rita Angélica / Vega-Morales, David / Santoyo-Fexas, Leticia / Garza-Elizondo, Mario Alberto / Mendiola-Jiménez, Andrés / González Marquez, Karina Itzel / Carrillo-Haro, Berenice

    International journal of immunogenetics

    2023  Volume 51, Issue 1, Page(s) 1–9

    Abstract: Objective: Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP) are commonly used for diagnosis of rheumatoid arthritis (RA), although other rheumatic diseases with arthritis can test positive. This study aimed to determine ... ...

    Abstract Objective: Rheumatoid factor (RF) and anti-cyclic citrullinated peptide antibody (anti-CCP) are commonly used for diagnosis of rheumatoid arthritis (RA), although other rheumatic diseases with arthritis can test positive. This study aimed to determine the cutoff values for RF and anti-CCP with the best diagnostic performance in a sample of patients with RA, compared with other rheumatic diseases.
    Methods: This was a descriptive, prospective study. EUROINMMUN enzyme-linked immunosorbent assays for RF isotypes immunoglobulin (Ig) A (IgA), IgG and IgM and third-generation assay IgG for anti-CCP were used in serum samples of patients with RA, other rheumatic diseases and healthy subjects. The cutoff with the best diagnostic performance was determined by the Youden Index and receiver operating characteristic analysis Results: Three hundred and thirty-two serum samples were analysed. The cutoffs proposed in our population were for RF in RA patients versus other rheumatic diseases, and healthy subjects IgM 135 IU/mL, for each disease, compared with RA, were psoriatic arthritis (Psa) IgA 47.2 IU/mL, clinically suspicious arthralgia (CSA) IgA 39.5 IU/mL, primary Sjögren's syndrome (pSS) IgM 180.6 IU/mL, systemic lupus erythematosus (SLE) IgA 42.6 IU/mL, primary fibromyalgia (pFM) IgM 68.6 IU/mL, osteoarthritis (OA) IgM 48 IU/mL, gout IgM 117 IU/mL and healthy IgM 16.3 IU/mL. For anti-CCP, in RA patients versus other rheumatic diseases, and healthy subjects 6.95 IU/mL, for each disease, compared with RA, were Psa 6.8 IU/mL, CSA 9.95 IU/mL, pSS 20.7 IU/mL, SLE 6 IU /mL, pFM 11.8 IU/mL, OA 11.9 IU/mL, gout 5 IU/mL and healthy 5 IU/mL.
    Conclusion: Irrespective of the manufacturer's suggested cutoff, the RA versus differential diagnosis cutoffs must be considered.
    MeSH term(s) Humans ; Rheumatoid Factor ; Diagnosis, Differential ; Anti-Citrullinated Protein Antibodies ; Prospective Studies ; Arthritis, Rheumatoid ; Autoantibodies ; Lupus Erythematosus, Systemic ; Rheumatic Diseases/diagnosis ; Immunoglobulin G ; Immunoglobulin M ; Immunoglobulin A ; Gout/diagnosis ; Peptides ; Enzyme-Linked Immunosorbent Assay
    Chemical Substances Rheumatoid Factor (9009-79-4) ; Anti-Citrullinated Protein Antibodies ; Autoantibodies ; Immunoglobulin G ; Immunoglobulin M ; Immunoglobulin A ; Peptides
    Language English
    Publishing date 2023-11-06
    Publishing country England
    Document type Journal Article
    ZDB-ID 2177883-8
    ISSN 1744-313X ; 1744-3121
    ISSN (online) 1744-313X
    ISSN 1744-3121
    DOI 10.1111/iji.12643
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Education and treatment adherence during the COVID-19 pandemic. Response to: 'Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic' by Khabbazi

    Pineda-Sic, Rita Angélica / Serna-Peña, Griselda / Cardenas-de la Garza, Jesus Alberto / Torres-Castillo, Sergio A / Galarza-Delgado, Dionicio Angel / Flores-Alvarado, Diana Elsa

    Annals of the rheumatic diseases

    2020  Volume 81, Issue 10, Page(s) e201

    MeSH term(s) COVID-19 ; Humans ; Medication Adherence ; Pandemics ; Rheumatic Diseases/drug therapy ; Treatment Adherence and Compliance
    Keywords covid19
    Language English
    Publishing date 2020-09-07
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2020-218791
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience.

    Pineda-Sic, Rita Angélica / Galarza-Delgado, Dionicio Angel / Serna-Peña, Griselda / Castillo-Torres, Sergio A / Flores-Alvarado, Diana Elsa / Esquivel-Valerio, Jorge A / Hernández-Galarza, Iván De Jesús

    Annals of the rheumatic diseases

    2020  Volume 80, Issue 6, Page(s) e85

    MeSH term(s) Antirheumatic Agents/therapeutic use ; COVID-19 ; Humans ; Hydroxychloroquine/therapeutic use ; Latin America/epidemiology ; Pandemics ; Rheumatic Diseases/drug therapy ; Rheumatic Diseases/epidemiology ; Treatment Adherence and Compliance
    Chemical Substances Antirheumatic Agents ; Hydroxychloroquine (4QWG6N8QKH)
    Keywords covid19
    Language English
    Publishing date 2020-06-23
    Publishing country England
    Document type Letter ; Comment
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2020-218198
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: Characteristics and evolution of 38 patients with rheumatic diseases and COVID-19 under DMARD therapy.

    Galarza-Delgado, Dionicio Ángel / Serna-Peña, Griselda / Compeán-Villegas, Jesús Eduardo / Cardenas-de la Garza, Jesus Alberto / Pineda-Sic, Rita Angélica / Colunga-Pedraza, Iris Jazmín / Vega-Morales, David / Pérez-Barbosa, Lorena / Skinner-Taylor, Cassandra Michelle / Flores-Alvarado, Diana Elsa

    Clinical rheumatology

    2020  Volume 40, Issue 3, Page(s) 1197–1199

    MeSH term(s) Adult ; Aged ; Aged, 80 and over ; Antirheumatic Agents/therapeutic use ; COVID-19/complications ; COVID-19/therapy ; Female ; Humans ; Male ; Mexico ; Middle Aged ; Rheumatic Diseases/complications ; Rheumatic Diseases/drug therapy ; Treatment Outcome ; Young Adult
    Chemical Substances Antirheumatic Agents
    Language English
    Publishing date 2020-11-24
    Publishing country Germany
    Document type Letter
    ZDB-ID 604755-5
    ISSN 1434-9949 ; 0770-3198
    ISSN (online) 1434-9949
    ISSN 0770-3198
    DOI 10.1007/s10067-020-05510-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: Low-dose rituximab therapy in steroid-refractory thrombocytopenia due to systemic lupus erythematosus.

    Ilizaliturri-Guerra, Octavio / Uriarte-Botello, Rodolfo / Pineda-Sic, Rita Ángelica / Serna-Peña, Griselda / Garza-Elizondo, Mario Alberto / Galarza-Delgado, Dionicio Ángel / Leal-Bramasco, Ana Sofía / Elizondo-Solís, César Vidal / Santoyo-Fexas, Leticia / Villarreal-Alarcón, Miguel Ángel

    Rheumatology international

    2020  Volume 40, Issue 10, Page(s) 1717–1724

    Abstract: Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by multi-organ symptomatology. 16% of the patients with autoimmune thrombocytopenia have SLE and are associated with high mortality. Intravenous methylprednisolone or high-dose ... ...

    Abstract Systemic lupus erythematosus (SLE) is an autoimmune disease, characterized by multi-organ symptomatology. 16% of the patients with autoimmune thrombocytopenia have SLE and are associated with high mortality. Intravenous methylprednisolone or high-dose steroids are the first-line treatments in those patients who experienced life-threatening bleeding or have a severely low platelet count, whereas a second line includes splenectomy, as well as other immunosuppressive agents as monotherapy or combined therapy, including azathioprine, cyclophosphamide, cyclosporine, and mycophenolate mofetil. However, response rates of these therapies vary considerably. Rituximab (RTX) became a useful tool in the treatment of autoimmune diseases, due to the decrease of autoantibodies production. In addition, there is evidence that low doses of RTX (100 mg IV per week for 4 weeks) can have a similar effect compared to the standard dose. The objective of this study was to describe the response to low doses of RTX in patients with lupus-induced thrombocytopenia. We present a report of four female patients with newly diagnosed SLE, accompanied by purpuric syndrome and severe thrombocytopenia (< 30 × 109/L) as the clinical debut that was refractory to glucocorticoids (GC) therapy and treated with low doses of RTX. By week 5, complete response (> 100 × 109/L) was achieved in two patients, partial response (> 50 × 109/L) in 1 patient, and no response in one patient. There is little information on the treatment of SLE-associated autoimmune thrombocytopenia. The most extensive study found at the time of our search was the study of 10 Asian patients. They found that 80% of the patients responded by week four and maintained until week 24 of follow-up. At week 36, a follow-up for two patients showed relapse; this occurred on patients with the most disease duration (> 5 years) and was associated with a lower response rate. In contrast, our study with four patients found that half of them presented a complete response: one patient added concomitant therapy with azathioprine (AZA) and another patient without the concomitant therapy. A third patient with a partial improvement, this was seen by week five of treatment. Moreover, a fourth patient who did not have a response by week five of treatment presented a clinical response in subsequent appointments with a count of > 100 at week 24. Those patients who required concomitant use of AZA were patients who had positive antiphospholipid serology. The use of low-dose RTX for the management of severe thrombocytopenia refractory to GC in patients with SLE has a good response. It could be a safe, economical, and effective therapy.
    MeSH term(s) Adolescent ; Adult ; Female ; Humans ; Immunologic Factors/administration & dosage ; Lupus Erythematosus, Systemic/complications ; Middle Aged ; Purpura, Thrombocytopenic, Idiopathic/drug therapy ; Purpura, Thrombocytopenic, Idiopathic/etiology ; Retrospective Studies ; Rituximab/administration & dosage
    Chemical Substances Immunologic Factors ; Rituximab (4F4X42SYQ6)
    Language English
    Publishing date 2020-08-14
    Publishing country Germany
    Document type Case Reports ; Journal Article ; Review
    ZDB-ID 8286-7
    ISSN 1437-160X ; 0172-8172
    ISSN (online) 1437-160X
    ISSN 0172-8172
    DOI 10.1007/s00296-020-04668-4
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article: Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience

    Pineda-Sic, Rita Angélica / Galarza-Delgado, Dionicio Angel / Serna-Peña, Griselda / Castillo-Torres, Sergio A / Flores-Alvarado, Diana Elsa / Esquivel-Valerio, Jorge A / Hernández-Galarza, Iván De Jesús

    Ann. rheum. dis

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #612710
    Database COVID19

    Kategorien

  7. Article: Education and treatment adherence during the COVID-19 pandemic. Response to: 'Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic' by Khabbazi et al

    Pineda-Sic, Rita Angélica / Serna-Peña, Griselda / Cardenas-de la Garza, Jesus Alberto / Torres-Castillo, Sergio A / Galarza-Delgado, Dionicio Angel / Flores-Alvarado, Diana Elsa

    Ann. rheum. dis

    Keywords covid19
    Publisher WHO
    Document type Article
    Note WHO #Covidence: #748780
    Database COVID19

    Kategorien

  8. Article ; Online: Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic

    Pineda-Sic, Rita Angélica / Galarza-Delgado, Dionicio Angel / Serna-Peña, Griselda / Castillo-Torres, Sergio A / Flores-Alvarado, Diana Elsa / Esquivel-Valerio, Jorge A / Hernández-Galarza, Iván De Jesús

    Annals of the Rheumatic Diseases

    a Latin American experience

    2020  , Page(s) annrheumdis–2020–218198

    Keywords Immunology ; General Biochemistry, Genetics and Molecular Biology ; Immunology and Allergy ; Rheumatology ; covid19
    Language English
    Publisher BMJ
    Publishing country uk
    Document type Article ; Online
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2020-218198
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

  9. Article ; Online: Education and treatment adherence during the COVID-19 pandemic. Response to

    Pineda-Sic, Rita Angélica / Serna-Peña, Griselda / Cardenas-de la Garza, Jesus Alberto / Torres-Castillo, Sergio A / Galarza-Delgado, Dionicio Angel / Flores-Alvarado, Diana Elsa

    Annals of the Rheumatic Diseases

    ‘Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic’ by Khabbazi et al

    2020  , Page(s) annrheumdis–2020–218791

    Keywords Immunology ; General Biochemistry, Genetics and Molecular Biology ; Immunology and Allergy ; Rheumatology ; covid19
    Language English
    Publisher BMJ
    Publishing country uk
    Document type Article ; Online
    ZDB-ID 7090-7
    ISSN 1468-2060 ; 0003-4967
    ISSN (online) 1468-2060
    ISSN 0003-4967
    DOI 10.1136/annrheumdis-2020-218791
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    More links

    Kategorien

To top